Open Access

[Corrigendum] Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer

  • Authors:
    • Norihiko Suzuki
    • Fumio Nakagawa
    • Teiji Takechi
  • View Affiliations

  • Published online on: May 5, 2021     https://doi.org/10.3892/ol.2021.12772
  • Article Number: 511
  • Copyright : © Suzuki et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

View Figures

Related Articles

Journal Cover

July-2021
Volume 22 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Suzuki N, Nakagawa F and Takechi T: [Corrigendum] Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer. Oncol Lett 22: 511, 2021
APA
Suzuki, N., Nakagawa, F., & Takechi, T. (2021). [Corrigendum] Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer. Oncology Letters, 22, 511. https://doi.org/10.3892/ol.2021.12772
MLA
Suzuki, N., Nakagawa, F., Takechi, T."[Corrigendum] Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer". Oncology Letters 22.1 (2021): 511.
Chicago
Suzuki, N., Nakagawa, F., Takechi, T."[Corrigendum] Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer". Oncology Letters 22, no. 1 (2021): 511. https://doi.org/10.3892/ol.2021.12772